Analysts Set iRhythm Technologies (NASDAQ:IRTC) PT at $219.23

Shares of iRhythm Technologies (NASDAQ:IRTC) have received an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $211.6154.

IRTC has been the topic of several recent research reports. Freedom Capital upgraded iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. Citigroup increased their target price on shares of iRhythm Technologies from $205.00 to $242.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Wells Fargo & Company lowered their target price on shares of iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating for the company in a report on Friday. BTIG Research lifted their price target on shares of iRhythm Technologies from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $244.00 price objective on shares of iRhythm Technologies in a research report on Monday, January 12th.

iRhythm Technologies Trading Down 5.0%

IRTC opened at $150.96 on Wednesday. The firm has a market cap of $4.86 billion, a P/E ratio of -107.83 and a beta of 1.06. iRhythm Technologies has a 12 month low of $92.52 and a 12 month high of $212.00. The company has a current ratio of 4.63, a quick ratio of 4.50 and a debt-to-equity ratio of 5.32. The stock has a 50-day moving average of $164.65 and a 200 day moving average of $171.29.

iRhythm Technologies (NASDAQ:IRTC) last issued its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.27. The business had revenue of $208.89 million for the quarter, compared to the consensus estimate of $202.61 million. iRhythm Technologies had a negative return on equity of 31.44% and a negative net margin of 5.96%.The company’s quarterly revenue was up 27.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.04) earnings per share. As a group, research analysts forecast that iRhythm Technologies will post -1.98 EPS for the current year.

Key Stories Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

Insider Buying and Selling

In other news, insider Patrick Michael Murphy sold 2,478 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $458,008.74. Following the sale, the insider directly owned 53,281 shares in the company, valued at approximately $9,847,927.23. This represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Chad Patterson sold 280 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $51,752.40. Following the sale, the insider directly owned 43,387 shares of the company’s stock, valued at $8,019,219.21. This represents a 0.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.10% of the company’s stock.

Institutional Trading of iRhythm Technologies

A number of large investors have recently made changes to their positions in IRTC. Quantbot Technologies LP purchased a new stake in shares of iRhythm Technologies during the second quarter valued at about $3,578,000. Federated Hermes Inc. raised its stake in shares of iRhythm Technologies by 45.4% during the 3rd quarter. Federated Hermes Inc. now owns 70,401 shares of the company’s stock worth $12,108,000 after acquiring an additional 21,977 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of iRhythm Technologies by 507.3% during the 2nd quarter. Osaic Holdings Inc. now owns 9,292 shares of the company’s stock worth $1,431,000 after acquiring an additional 7,762 shares in the last quarter. Jump Financial LLC purchased a new stake in iRhythm Technologies during the second quarter valued at approximately $9,668,000. Finally, Walleye Capital LLC acquired a new stake in iRhythm Technologies in the second quarter valued at approximately $11,366,000.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.